1.Bibliometric analysis on research hotspots on HIV post-exposure prophylaxis related articles in the world, 2000-2017.
T Y LU ; X MAO ; E L PENG ; J M LI ; W Q GENG ; Y J JIANG ; J J XU
Chinese Journal of Epidemiology 2018;39(11):1501-1506
Objective: To analyze and reveal the distribution, research hotspots and study trend of worldwide published articles correlated with HIV/AIDS post-exposure prophylaxis (PEP), and provide information for related studies in China. Methods: CiteSpace software 5.1 was used to visualize all related papers in the web of science database published during 2000-2017. Results: The average growth rate of international PEP-related papers was 10.78%,and number of published papers in 2016 was highest (n=34), relevant research hotspots have shifted from the prevention of occupational HIV exposure to the prevention of non-occupational HIV exposure in group at high risk, such as MSM, in recent years. Clustering analysis classified research hotspots into three categories, including risk reduction through enhanced intervention, current status of global HIV PEP and German-Austrian Recommendation. Conclusions: Non-occupational HIV PEP in groups at high-risk, especially MSM, has received increasing attention in recent years, the research of PEP mainly focus on improving the awareness and use of PEP in MSM and compliance in the course of medication. In the context of severe HIV epidemic in MSM without effective control in China, PEP should be strengthened to assess and explore the risk of HIV infection in MSM to provide reference for medical personnel and related departments to implement HIV non-occupation exposure blockade and formulate PEP medication.
Anti-HIV Agents/administration & dosage*
;
Bibliometrics
;
Biomedical Research
;
China
;
HIV
;
HIV Infections/prevention & control*
;
Homosexuality, Male
;
Humans
;
Male
;
Periodicals as Topic
;
Post-Exposure Prophylaxis/methods*
2.Evaluation of in vitro antimicrobial susceptibility of Bacillus anthracis strains isolated during anthrax outbreaks in Italy from 1984 to 2017
Viviana MANZULLI ; Antonio FASANELLA ; Antonio PARISI ; Luigina SERRECCHIA ; Adelia DONATIELLO ; Valeria RONDINONE ; Marta CARUSO ; Sabine ZANGE ; Alina TSCHERNE ; Nicola DECARO ; Carmine PEDARRA ; Domenico GALANTE
Journal of Veterinary Science 2019;20(1):58-62
Anthrax, caused by Bacillus anthracis, is a non-contagious infectious disease that affects a wide range of animal species (primarily ruminants) including humans. Due to the often-fatal outcome in humans, quick administration of definitely effective antimicrobials is crucial either as prophylaxis or as a clinical case therapy. In this study, 110 B. anthracis strains, temporally, geographically, and genetically different, isolated during anthrax outbreaks in Italy from 1984 to 2017, were screened using a broth microdilution method to determine their susceptibility to 16 clinically relevant antimicrobial agents. The strains were isolated from various matrices (human, animal, and environmental samples) and were representative of thirty distinct genotypes previously identified by 15-loci multiple-locus variable-number of tandem repeats analysis. The antimicrobials tested were gentamicin, ceftriaxone, streptomycin, penicillin G, clindamycin, chloramphenicol, vancomycin, linezolid, cefotaxime, tetracycline, erythromycin, rifampin, amoxicillin, ciprofloxacin, doxycycline, and trimethoprim. All isolates were susceptible to most of the tested antimicrobials, with the exception of trimethoprim for which all of them showed high minimal inhibitory concentration values. An intermediate level of susceptibility was recorded for ceftriaxone and cefotaxime. Although the Centers for Disease Control and Prevention recommend the use of doxycycline, ciprofloxacin, penicillin G, and amoxicillin for treatment of human cases and for post-exposure prophylaxis to anthrax spores, this study shows a high degree of in vitro susceptibility of B. anthracis to many other antimicrobials, suggesting the possibility of an alternative choice for prophylaxis and therapy.
Amoxicillin
;
Animals
;
Anthrax
;
Anti-Infective Agents
;
Bacillus anthracis
;
Bacillus
;
Cefotaxime
;
Ceftriaxone
;
Centers for Disease Control and Prevention (U.S.)
;
Chloramphenicol
;
Ciprofloxacin
;
Clindamycin
;
Communicable Diseases
;
Disease Outbreaks
;
Doxycycline
;
Erythromycin
;
Genotype
;
Gentamicins
;
Humans
;
In Vitro Techniques
;
Italy
;
Linezolid
;
Methods
;
Microbial Sensitivity Tests
;
Penicillin G
;
Post-Exposure Prophylaxis
;
Rifampin
;
Spores
;
Streptomycin
;
Tandem Repeat Sequences
;
Tetracycline
;
Trimethoprim
;
Vancomycin